Sponsor Dossier
Link Pharmaceuticals
Sponsor Dossier for Link Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACETYLCYSTEINE-LINK
- Brand: ADRENALINE-LINK
- Brand: ALACARE
- Brand: ALLMERCAP
- Brand: ATACAND
- Brand: CEENU
- Brand: CHLOROMYCETIN
- Brand: COLISTIN
- Device (sponsor): Medicine administration kit, oral
- Device (sponsor): Organ preservation solution
- Device (sponsor): Organ preservation solution
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): STuberculin-allergy syringe/retractable-needle
- Device (sponsor): Wet wipe
About
Link Pharmaceuticals is an Australian Private Company with ABN 73010971516, registered in NSW and currently active.
Portfolio
Link Pharmaceuticals maintains 29 brands on the ARTG, with 28 indexable brands and 25 brands with Product Information on file. Seven brands have PBS-listed items, six have PBAC outcomes on record, and six have AusPARs on record. Notable brands include Acetylcysteine-Link, Adrenaline-Link, Alacare, Allmercap, Atacand, Ceenu, Chloromycetin, Colistin, Etopophos, Fampyra, Foscavir and Hydrea.
Therapeutic focus —
Oncology: 8 brands — Neurology: 5 brands — Infectious Disease: 5 brands — Cardiology: 3 brands — Immunology: 2 brands — Pain & Anaesthesia: 1 brand — Dermatology: 1 brand — Endocrinology: 1 brand — Ophthalmology: 1 brand — Gastroenterology: 1 brand — Hepatology: 1 brand
PBS footprint
Seven of Link Pharmaceuticals' brands have at least one PBS-listed item, with the portfolio last touching the PBS schedule on 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Link Pharmaceuticals is dated 1 March 2025, with six brands holding PBAC outcomes on record. The latest AusPAR is dated 3 October 2023, with six brands holding AusPARs on record.